Novartis (NYSE:NVS) is one of the planet's top drug manufacturers and its 3% dividend yield makes it a staple in dividend investor portfolios.

However, Novartis is facing significant threats from competitors Biogen Idec (NASDAQ:BIIB) and Regeneron (NASDAQ:REGN) which could crimp sales even as generic competition heats up for Novartis' multi-billion blockbuster drug Diovan.

Source: Novartis

In the following slideshow, you'll learn more about Novartis' most important drugs and the threats and opportunities the lie ahead for them.